ReviewAdvanced healthcare materials2019
Drug Delivery Strategies for the Treatment of Metabolic Diseases.
Review in Advanced healthcare materials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 65 citations in OpenAlex.
- Application of edible fungi in gut microbiota regulation.NPJ science of food · 2025Review
- Advances in microneedle-based drug delivery system for metabolic diseases: structural considerations, design strategies, and future perspectives.Journal of nanobiotechnology · 2025Review
- Ethosome-Based Transdermal Drug Delivery: Its Structural Components, Preparation Techniques, and Therapeutic Applications Across Metabolic, Chronic, and Oncological Conditions.Pharmaceutics · 2025Review
- Liposome-mediated macrophage reprogramming: emerging strategies for chronic disease therapy.Frontiers in immunology · 2025Review
- Cutting-edge microneedle innovations: Transforming the landscape of cardiovascular and metabolic disease management.iScience · 2024Review
- Exploring Ethnobotany in the Catalan Linguistic Area: Traditional Plant-Based Knowledge for Addressing Gastrointestinal, Metabolic, and Nutritional Disorders.Plants (Basel, Switzerland) · 2024Article
- Correlation between Complement C1q A Chain (Iranian journal of public health · 2024Article
- β-blockers and metabolic modulation: unraveling the complex interplay with glucose metabolism, inflammation and oxidative stress.Frontiers in pharmacology · 2024Review
- The Role of cGAS-STING Signalling in Metabolic Diseases: from Signalling Networks to Targeted Intervention.International journal of biological sciences · 2024Review
- Nano-Drug Delivery Systems in Oral Cancer Therapy: Recent Developments and Prospective.Pharmaceutics · 2023Review
- Lipoprotein Particles as Shuttles for Hydrophilic Cargo.Membranes · 2023Article
- Nucleic acid nanoassembly-enhanced RNA therapeutics and diagnosis.Acta pharmaceutica Sinica. B · 2023Review
- Surface-modified nanotherapeutics targeting atherosclerosis.Biomaterials science · 2022Review
- Multi-functional self-assembly nanoparticles originating from small molecule natural product for oral insulin delivery through modulating tight junctions.Journal of nanobiotechnology · 2022Article
- Analysis on the Effect of Metformin Hydrochloride Combined with Insulin Pump for Gestational Diabetes Mellitus.Iranian journal of public health · 2022Article
- The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases.Genes & diseases · 2021Review
- Regulatory role and mechanism of mMolecular therapy oncolytics · 2021Review
- Deep Eutectic Solvents as Active Pharmaceutical Ingredient Delivery Systems in the Treatment of Metabolic Related Diseases.Frontiers in pharmacology · 2021Review
- Tumor pH-responsive metastable-phase manganese sulfide nanotheranostics for traceable hydrogen sulfide gas therapy primed chemodynamic therapy.Theranostics · 2020Article
- RNACell & bioscience · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Metabolic diseases occur when normal metabolic processes are disrupted in the human body, which can be congenital or acquired. The incidence of metabolic diseases worldwide has reached epidemic proportions. So far, various methods including systemic drug therapy and surgery are exploited to prevent and treat metabolic diseases. However, current pharmacotherapeutic options for treatment of these metabolic disorders remain limited and ineffective, especially reducing patient compliance to treatment. Therefore, it is desirable to exploit effective drug delivery approaches to effectively treat metabolic diseases and reduce side effects. This brief review summarizes novel delivery strategies including local, targeted, and oral drug delivery strategies, as well as intelligent stimulus-responsive drug delivery strategy, for the treatment of metabolic disorders including diabetes, obesity, and atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.